






















Best wishes to DBD staff retiring this year. Thank you for your outstanding dedication and 
contributions that have added tremendously to DBD’s success. 
DBD Immunology Laboratories Chief George Carlone, PhD has done extensive work on 
evaluation of bacterial vaccines, development of assays for vaccine evaluation, and training on 
immunologic techniques. He developed and standardized reference assays for vaccine evaluation 
(e.g., ELISA, serum bactericidal assays, opsonophagocytosis, adherence assays, proteomics, 
animal models, luminex, flow cytometric applications, analysis models). George was involved 
early on in the development of the vaccine MenAfriVac™ that is being used with great success 
to protect against meningitis in Africa—he directed serological evaluations in PATH’s sponsored 
trials for the introduction and licensure of the vaccine. About that work, George has said, “Our 
tests on serum from nearly 5,000 study participants aided development of this new vaccine—we are all proud 
to be a part of this global collaboration that has the potential to save thousands of lives.” With more than 170 
publications, he has received numerous awards and recognitions; his contributions are far reaching with 17 granted 
patents and 14 patents applied for. He has been with CDC for 32 years.
Scott E. Johnson, MS, is lead of the Serum Bactericidal Antibody Assay Team in MVPDB’s 
Immunology Laboratories. He has participated on various Legionnaires’ disease studies, 
including isolating and identifying Legionella by using chicken egg yolk culturing techniques 
and cellular fatty acid mapping through gas liquid chromatography analysis. He is the curator 
for CDC’s stock inventories of leptospirosis and anthrax. Scott has worked in the pneumococcal 
and meningococcal vaccine development for 19 years, where he advanced measurement 
of functional serum bactericidal antibodies (SBA) for four major meningococcal serogroups 
including one used for licensure of meningococcal vaccines including MenAfrivacTM. He 
was recognized in 1979 with the CDC Commendation Award “For significant contributions in the isolation of 
Legionnaires’ disease bacterium from inanimate sources;” in 1983 was co-recipient of the Charles C. Shepard Award 
for “Outstanding contribution to CDC/ATSDR mission and public health,” and in 1990 received a Special Service 
Award for “Contribution to the development of a highly sensitive antibody assay for evaluating vaccines against 
meningococcal disease.” Scott retires this year after 39 years with CDC.
MVPDB laboratorian Sandy Martin was one of the HHSinnovates Winners in 2010 for her work 
with colleagues on the CDC Lab Recycling Pilot Program they designed to help avoid substantial 
dumping of plastic containers which had held biohazard materials into waste landfills by using 
a process for cleaning the containers after use to be suitable for recycling. Sandy has been a 
member of the Sigma Xi Scientific Research Society for several years and was secretary for the 
CDC Chapter of Sigma Xi from 2010 to 2012. Sandy has been with CDC for 12 years and has 
always promoted quality as an individual responsibility.
After receiving her PhD in microbiology from Emory University, Jacquelyn Sampson decided 
on a career in research rather than teaching and joined CDC. That was 32 years ago and she 
has since acquired 8 patents (6 granted and 2 pending). Her career has focused on improving 
diagnosis and prevention of the leading bacterial cause of pneumonia. Sampson was a key 
member of the team that received the 2009 CDC Director’s Innovation Award in research and 
technology for her work with development of pneumococcal surface antigen A(PsaA), a protein 
that is present in all pneumococci and has been evaluated as a vaccine candidate. Jackie says, “I 
have found a great pleasure in mentoring minority students interested in research careers.”
Elizabeth Zell, MStat, is a mathematical statistician in the DBD OD. Elizabeth is credited with helping to develop and 
implement the National Immunization Survey and is an internationally recognized expert on methods for vaccine 
coverage assessment and vaccine evaluation. Among her many projects of note has been her 
work on early onset neonatal sepsis, a range of studies documenting the effects of PCV7 on 
pneumococcal disease in the United States, and studies of pneumococcal vaccine effectiveness 
in Africa. She has been the lead statistician for ABCs, one of CDC’s premier surveillance and 
research platforms, and much of the success of that program is because of Elizabeth’s work. 
Elizabeth says, “Not all statistics is complex data analysis; sometimes the simplest descriptive 
analysis tells the important story about a disease or outbreak.” Elizabeth has been with CDC for 
32 years.
This end of the 
year DBD Bulletin 
is more than just an 
opportunity to highlight 
some of our activities. 
This issue speaks for 
all the great work going 
on at the division.
Thank you for all your 
tireless efforts that 




monitoring impact of 
various  interventions, 
thus saving and 
improving lives all over 
the United States and 
the world. 
I wish you restful and 
happy holidays with all 
your loved ones!
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Amanda Cohn explained the Advisory Committee on Immunization 
Practices’ (ACIP) fall 2011 recommendation for a booster dose of 
meningococcal conjugate vaccine for adolescents in the 2012 Medscape 
video “Clarifying Meningococcal Booster Dose Recommendations.”
Kathleen Dooling discussed pneumonia, preventive steps, and the 
need to stay up-to-date on vaccinations in her podcast on preventing 
pneumonia.
Change in Administration for Anthrax Vaccine 
Data from CDC’s Anthrax Vaccine Research Program (AVRP) provided 
the evidence for FDA approval in May of changes to the label for pre-
exposure use of anthrax vaccine adsorbed (AVA, BioThrax). Under the 
new 3-dose primary series recommendation, AVA will safeguard 66% 
more personnel in one-third the time with an anticipated 50% reduction 
in local adverse events, and will require only half the number of doses 
compared with the original licensed schedule. It will also provide 
a significant cost reduction per schedule. FDA approval of a 3-dose 
primary series for AVA (BioThrax) represents the successful culmination 
of this CDC program. DBD/MVPDB will continue to work with the 
AVA manufacturer to explore additional reductions in the booster 
schedule. The Microbial Pathogenesis and Immune Response (MPIR) 
Laboratory and Brian Plikaytis from the Statistics Office made significant 
contributions to this research.
Tdap Vote: Streamlining the Adult Recommendation 
In February, the Advisory Committee on Immunization Practices (ACIP) 
voted to recommend that all adults aged 19 years and older who have 
not yet received a dose of Tdap should receive a single dose. Tdap can be 
administered regardless of interval since last tetanus or diphtheria-toxoid 
containing vaccine.
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Leonard Mayer recorded a discussion of invasive meningococcal disease based on a 
study about invasive meningococcal capsular group Y disease in England and Wales 








Diseases (ISPPD) in 
Iguacu Falls, Brazil, 
where RDB staff 
presented 28 oral 
and poster presen-
tations. Jennifer 
Verani, Lesley McGee, Laura Conklin and Gloria Carvalho also participated in the 
bi-annual symposium that raises global awareness and improves standards of diagnosis, 
prevention and treatment of pneumococcal disease.
Elizabeth Zell with Claire von Mollendorf from the Centre for Respiratory Diseases 
and Meningitis (CRDM) in Johannesburg, South Africa, helping Claire learn to use 
IVEware to multiply impute for missing data. Adjusting for missing information on HIV 
status is needed for monitoring pneumococcal disease trends through the GERMS  
surveillance system.
In 2012, DBD staff conducted lab trainings and workshops in 15 international 
locations, including in Australia, Brazil, Burkina Faso, Central African Republic, 
Cameroun, DR Congo, Gambia, Ghana, Guatemala, Kenya, Vellore, India, Korea, 
Mongolia, Mozambique and Thailand.
Quarter 2
Pertussis - a Never-Ending Story? 
Chinese immigrants in Washington (WA) state call pertussis the “100-day 
cough.” Other ethnic groups in the state, the first in the nation to declare 
a pertussis epidemic in 2012, have no words in their own language to 
describe pertussis, or whooping cough.
Pertussis is a highly contagious bacterial disease that affects all ages, 
but is most dangerous for infants. To prevent pertussis, 5 doses of DTaP 
vaccine are given to children and Tdap is recommended for everyone 11 
years or older, especially pregnant women and those in close contact 
with infants.
The United States has had record-high numbers of reported cases of 
pertussis this year, with over 36,000 cases and 16 deaths reported 
through late November. In April 2012, in WA—where there is a widely 
diverse ethnic population  often isolated by language, customs and 
location—the state’s Secretary of Health declared a pertussis epidemic. 
By June 16, there were 2,520 cases reported (37.5 cases per 100,000 
residents) in WA, a 1,300% increase compared with the same period 
in 2011. This is the highest number of pertussis cases reported in WA 
since 1942. Compared with the incidence in WA, the national incidence 
for the same period in 2012 was lower overall (4.2 cases per 100,000 
population).
In response to this ongoing epidemic, the WA State Department of 
Health established an incident command structure to coordinate 
epidemic response and surveillance activities and reached out to CDC 
for technical support. CDC mobilized very quickly and DBD responded 
by providing personalized outreach to media, consumers and providers, 
as well as epidemiologic and laboratory support and leadership on 
guidelines and policy. Our involvement is on-going.
During the height of the declared epidemic, DBD assisted WA by 
checking the accuracy of the lab testing performed in local hospitals and 
laboratories. To further confirm Bordetella pertussis as the etiology and 
evaluate the contribution of other Bordetella species, multi-target PCR 
assays were performed on a subset of specimens submitted to CDC by 
WA Public Health Laboratories and a commercial laboratory.
Last spring, CDC collaborated with the WA State Department of 
Health on a series of media roundtables about the pertussis epidemic, 
health risks, and the importance of vaccinating children and adults. 
Media outlets serving WA Native American, Asian American, Chinese, 
Japanese, Korean, Vietnamese, Filipino, Hispanic and African immigrant 
communities participated in the media roundtables that were designed 
to drive home to ethnic communities the critical importance of getting 
vaccinated.
Stacey Martin (left) 
took part in the media 
roundtable to help educate 
WA’s very diverse media 
about the devastation of 
pertussis so that they could 
inform their audiences—in 
their own languages—of 
how important it is to 
protect babies and young children—really everyone in the family—
through vaccination. She helped to put a human face on the pertussis 
epidemic.
Information about pertussis was translated into multiple languages and 
made available on the Internet. Roadside billboards still dot the WA 
skyline and colorful poster ads on 
mass transit remain in place. Our 
healthcare provider education is 
focusing on clinical presentation, 
appropriate diagnostic testing, 
and treatment and prevention 
recommendations with specific 
emphasis on vaccination to prevent 
transmission.
Nationally, and in WA, pertussis 
is being reported in teenagers. 
DBD took advantage of the 
opportunity to learn how well and for 
how long Tdap vaccines protect teenagers 
against pertussis by collaborating with 
the health department on a large-scale 
evaluation conducted by rotating teams 
of epidemiologists who looked at the 
state’s vaccine database and made visits 
to doctors’ offices to review vaccine 
histories of teenagers with and without 
pertussis.
By the end of September, 4,190 cases 
of pertussis had been reported in WA, 
almost 10 times more than the same 
time period in 2011 when 427 cases were 
reported. Given the number of cases, it is 
fortunate that there have been no reported fatalities.
Tom Clark appeared on CNN 
and WebMD to discuss the WA 
outbreak and, in his editorial 
commentary published in the 
journal Pediatrics in August, 
Tom noted, “92 to 95% of the 
population must be protected 
in order to halt transmission 
of pertussis. While childhood 
diphtheria, tetanus toxoid and acellular pertussis vaccine (DTaP) coverage 
is 95%, the vaccines currently in use are approximately 85% effective 
overall; the evidence is increasing that immunity may wane more rapidly 
than anticipated.”
The ongoing pertussis epidemic in WA reflects the evolving epidemiology 
of pertussis in the United States. The collaboration between the agency’s 
staff in DBD and WA is a success story for what can be accomplished 
working at the state and local level to address disease outbreaks. The 
focus of prevention and control efforts has to be the protection of infants 
and others at greatest risk for severe disease and improving vaccination 
coverage in adolescents and adults, especially those who are pregnant. 
Pertussis vaccination remains the single most effective strategy for 
prevention of infection.
DBD continues to keep the Advisory Committee on Immunization 
Practices (ACIP) informed of our findings on outbreaks and surveillance 
activities in WA. ACIP will consider this information to carefully help 
guide discussions on how best to use vaccines to control pertussis, and 




Spanish-language billboard about 
pertussis in Washington state
EIS Officer Sarah Meyer (left) 
and Julia Chang (right), a CDC 
experience fellow, reviewed 











Rana Hajjeh attended the Nigerian National Vaccine Summit in Abuja, 
Nigeria. The high-level meeting of national and international delegates, 
including the First Lady of the Federal Republic of Nigeria, was organized 
to join forces with the international community to expand vaccine access 
nationwide with the goal of achieving universal vaccine coverage for all 
Nigerian children by the year 2015. Over one million Nigerian children 
under age 5 die annually from vaccine-preventable diseases.
The Epidemic Intelligence Service (EIS) hosted its 2012 annual scientific 
conference for the national and international public health community 
in Atlanta. Completing the two-year post-graduate training program of 
service and on-the-job learning in the practice of applied epidemiology 
are Alicia Demirjian, a graduate 
of the American University of 
Beirut, and Aaron Harris, a 
graduate of Tufts University, in 
the RDB while Hajime Kamiya, 
a graduate of the Mie University 
School of Medicine, and Stephen 
Ko, a graduate of the Medical 
College of Georgia, are stationed 
in the MVPDB.
Darcia Johnson was the featured 
speaker for the spring NCIRD 
Director’s Call to discuss plans 
for the 2012 Get Smart About 
Antibiotics Week activities. 
Public and private partners from 
around the country participate 
in the quarterly calls.
Stacey Martin (DBD/MVPDB) was the speaker for “Coughing up the 
Facts on Pertussis—Emerging Trends and Vaccine Recommendations,” a 
Current Issues in Immunization NetConference.
NCIRD and many partners joined ABC News’ senior health and medical 
editor Dr. Rich Besser for a live Twitter chat for World Meningitis Day, 
which had more than 4.5 million impressions. Amanda Cohn and Jessica 
MacNeil answered questions about meningitis and meningococcal 
vaccines.
The National Center for Public Health Laboratory Leadership of the 
Association of Public Health Laboratories (APHL) selected MVPDB’s 
Jarad Schiffer to join the fifth Cohort of the Emerging Leaders Program. 
Jarad will participate for a year in team building, skill development 
and interactive social and professional networking to address the 
current issues and problems characteristic of the current laboratory 
environment.
PCV13 Licensed for Adults 
and Recommended for Immunocompromised Adults 
FDA licensed PCV13 for adults age 50 years and older in December 
2011. At its June meeting, ACIP voted to recommend that adults 19 
years of age or older with immunocompromising conditions, functional 
or anatomic asplenia, CSF leaks or cochlear implants, and who have not 
previously received PCV13 or PPSV23 receive a single dose of PCV13 
followed by a dose of PPSV23 at least 8 weeks later. 
Chris Van Beneden provided expert guidance for an interview with 
TeleMundo on necrotizing fasciitis.
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Amanda Cohn, Rana Hajjeh, and Chris Van Beneden participated in the WHO annual 
NUVI meeting (New and Underutilized Vaccines) meeting in Marrakech, Morocco. Chris 
presented the talk “Measuring the impact of Streptococcus pneumoniae and 
Haemophilus influenzae type b conjugate vaccination: An introduction to WHO’s 
Vaccine Impact Manual” and Rana was part of an expert panel that discussed vaccine 
introduction in low middle income countries.
Claressa Lucas was featured in a CDC 
Connects story after she used her beekeeper 
skills to help remove a swarm of honey bees 
from CDC Health Rider Donnie Powell’s 
Harley-Davidson bike in the Building 16 
parking deck one afternoon last spring.
DBD staff Pam Cassiday, 
Amanda Faulkner, Cindy 
Hatcher, Lauri Hicks, Stacey 
Martin, Alison Patti, Tami 
Skoff, Emily Weston and 
Jonathan Wortham helped 
to raise funds for Children’s 














a surveillance epidemiologist with the Burkina Faso Ministry of Health, whose visit to 
the United States was funded by the International Conference on Emerging Infectious 
Diseases ICIED Leaders program as part of the group’s 8th meeting in Atlanta in April. 
Mr. Tarbangdo met with MVPDB staff working on meningitis and attended an Interme-
diate Epi Info training program along with MVPDB’s Amanda Faulkner, Sema Mandal 
and Jessica MacNeil.
Emily Weston (on 
right), ABCs, along 
with Melony Fortuin-
de Smidt from The 




SA) in South Africa  
at the 2012 ABCs 
Surveillance Officers’ 
Meeting where Melony 
presented on Haemophilus influenzae in South Africa.
Quarter 3
2012 NCIRD Honor Award Recipients 
The NCIRD Honor Awards are awarded annually from peer-submitted 
nomination narratives that thoroughly describe the nominee’s 
achievements. Nominations were reviewed and ranked for the 38 CDC/
ATSDR Award categories by a NCIRD Awards Committee. The highest 
ranking nominations were sent forward to the agency. DBD staff members 
honored this year are listed below:
Enhancing Laboratory Capacity—recognizing outstanding commitment 
to enhance the capacity and build sustainability of global laboratories 
to diagnose, treat and prevent bacterial diseases through training, 
consultations and collaborative research by laboratory staff across the 
division—a cast of 34.
Robert Gertz for Outstanding Team Player Award—During a time 
of high Streptococcus Laboratory team attrition, Robert voluntarily 
assumed vacated essential tasks with a high level of professionalism and 
production.
Gail Langley for Innovation in Surveillance Award—Gail’s award was in 
recognition of outstanding creativity, innovation, and persistence with 
leading CDC’s ABCs in new directions.
Tamara Pillishvili for Rising to the Challenge Award—This award was 
presented in recognition of Tamara’s work in rising to the challenge of 
leading ACIP’s first discussions on adult pneumococcal conjugate vaccine 
use and coordinating a cross-center cleaner-burning stove assessment in 
Kenya.
Stephanie Schrag for Excellence in Leadership Award—Stephanie 
provided key input to several activities that were new for CDC, including 
evaluations of better cookstoves to reduce indoor air pollution, an 
evaluation of the causes of neonatal sepsis using cutting edge techniques 
and development of an app to help clinicians use CDC’s guidelines for 
neonatal group B strep disease (NCIRD nominated Stephanie for the 2012 
CDC Excellence in Leadership Award.)
DBD’s “Phlegm Fighters” helped NCIRD capture the much coveted 
Healthiest MEDIUM SIZED CIO Challenge Award in the CDC’s Healthiest 
CIO Challenge competition last summer! NCIRD eked out a victory ahead 
of archrival NCCDPHP by about one-hundredth of a percentage point. 
Anne Schuchat, who championed the center’s participation, in her note 
thanking NCIRD for participating said, “…we can all feel like competitive 
swimmers for this close a triumph.” Matt Moore was captain of the 
DBD “Phlegm Fighters,” with Chris Van Beneden, Kathleen Dooling, 
Laurel Garrison, Ruth Link-Gelles, Marsenia Harrison, Lauri Hicks, Natalia 
Kozak, Gayle Langley, Melissa Lewis, Jennifer Loo, Stacey Martin, Londell 
McGlone, Lesley McGee, Jenny Milucky, Alison Patti, Lucia Pawloski, 
Tamara Pilishvili, Tracy Pondo, Becky Roberts, Stephanie Schrag, Emily 
Weston, Cyndy Whitney, Jennifer Verani and Jeni Vuong making up the 
team. There was a lot of involvement in the challenge by other DBD 
staffers as well—many were inspired to participate on their own and 
record their activity on-line and in activities with other co-workers and 




CDR Jennifer Rabke Verani 
(USPHS) MD, MPH, a 
medical epidemiologist in 
RDB, was one of two CDC 
scientists who received 
the 2011 Presidential 
Early Career Awards for 
Scientists and Engineers 
(PECASE), the highest 
honor bestowed by the US 
government on science and 
engineering professionals 
in the early stages of their 
independent research careers. 
Jennifer visited the White 
House before the awards 
ceremony. Jennifer received the PECASE award for innovative public health research 
to improve child survival worldwide through enhanced perinatal disease prevention 













Media to review RDB’s poster on Mobilizing Group B Strep Prevention—GBS App for 
Obstetric and Neonatal Guidance that highlights design of a mobile web application 
to increase implementation of the Guidelines for Prevention of Perinatal Group B 
Streptococcal Disease by neonatal and obstetric clinicians.
DBD microbiologist Carla Talarico helps 
laboratorian Ranjith Jeyaraman don 
personal protective equipment before 
testing specimens for Streptococcus 
pneumoniae at the WHO Regional 
Reference Laboratory in Vellore, India, where 
she conducted lab capacity-building training 
for staff. Streptococcus pneumoniae, 
or pneumococcus, is a leading cause of 
morbidity and mortality among children 
worldwide and particularly in developing 
countries.
Steve Hadler (far right) with Cui Fuqiang from the CDC China 
National Immunization Program, DBD’s Jennifer Liang and former ISD 
Director Lance Rodewald (now detailed to WHO China Office) share 
dinner in Beijing, China in September, following participation in a 
national workshop on surveillance for meningococcal meningitis and 
pertussis, hosted by the China CDC National Immunization Program 











Helping the World Get Smat about Antibiotics 
Get Smart About Antibiotics Week 2012 
highlighted the threat of antibiotic resistance 
and the importance of appropriate antibiotic 
use nationally and globally. Promoting good 
antibiotic stewardship and collaborating with 
a host of partners to educate and inform 
the public about appropriate antibiotic use 
is a year round activity of the staff of DBD’s 
Get Smart: Know When Antibiotics Work 
campaign, which works in partnership with 
DHQP’s Get Smart for Healthcare campaign and state-based appropriate 
antibiotic use campaigns and partners to increase awareness of 
antibiotic resistance and the importance of appropriate antibiotic use. 
For the past 5 years, annually in November, the program collaborates 
with domestic and global partners to focus even more attention on the 
need for appropriate antibiotic use. Get Smart About Antibiotics Week 
2012 highlighted the threat of antibiotic resistance and the importance 
of appropriate antibiotic use nationally and globally. 
DBD highlights of this year’s activities in the 
United States included launch of the CDC/
IHI Driver Diagram and Change Package for 
Antibiotic Stewardship, a conceptual model 
to improve antibiotic use in hospitals that will 
reduce resistance and complications related 
to antibiotic use (e.g., Clostridium difficile 
diarrhea); Twitter chats; launch of a new 5-week 
television and YouTube campaign about only 
using antibiotics when necessary for parents of young children; release 
of a joint policy statement on antibiotic use; results of a Pew Health 
Group Poll; and information in various professional 
journals.
The program collaborated with the Pew Health 
Group on a poll to gauge Americans’ understanding 
of proper antibiotic use. Poll findings, released in a 
media briefing during Get Smart About Antibiotics 
Week, emphasized the importance of broad 
dissemination of Get Smart’s educational messages 
on appropriate antibiotic use and antibiotic 
resistance. The Pew Poll showed that nearly 9 
in 10 Americans recognize antibiotics as effective treatments 
for fighting bacterial infections like strep throat, but more 
than a third mistakenly believe antibiotics are also appropriate 
treatments for viral infections like the common cold. The poll 
also showed that most Americans (79%) understand that taking 
antibiotics when not needed may endanger their own health, 
but only 47% understand that doing this can also harm others. It 
is important that the public understand that antibiotic-resistant 
bacteria can quickly spread to family members, schoolmates, 
and co-workers—threatening the community with a new strain 
of infectious disease that is more difficult to cure and more 
expensive to treat. Most Americans (58%) have heard either a 
“fair amount” or a “great deal” about antibiotic resistance. Of 
those who have heard a great deal, 68% believe it is a “very big 
problem.”
A media telebriefing was held to release a “Joint Statement on 
Antibiotic Resistance with the U.S. Centers for Disease Control 
and Prevention (CDC) and 25 National Health Organizations” 
that outlines strategies to 
conserve and replenish 
antibiotic resources. In the 
statement, representatives 
from a range of fields 
concerned with human 
health jointly recognized a 
collective responsibility to 
protect the effectiveness 
of all antibiotics, calling 
for a greater coordination 
among all stakeholders in antibiotic effectiveness, including healthcare 
personnel, hospital administrators, policymakers, patients, and 
individuals working in medical centers, universities, and pharmaceutical 
companies to promote knowledge sharing and a mutual commitment 
to improving antibiotic use, a practice 
referred to as antibiotic stewardship.
In Australia, Antibiotic Awareness 
Week was officially supported by the 
Australasian Society for Infectious 
Diseases, the Australian Society 
for Antimicrobials, the Australian 
Commission for Safety and Quality in 
Health Care, and by NPS MedicineWise 
as part of a 5-year campaign to address 
antibiotic resistance in Australia.
In Canada, an ongoing initiative, AntibioticAwareness.ca, coordinated 
by numerous health-related organizations across the country that had 
partnered last year to promote the first Antibiotic Awareness Day in 
Canada extended its activities to hold a Canada Antibiotic Awareness 
Week.
As part of European Antibiotic Awareness Day 2012, experts from the 
European Centre for Disease Prevention and Control (ECDC), the World 
Health Organization Regional Office for Europe, the Directorate-General 
(DG) for Research and Innovation and the DG for Health and Consumers 
of the European Commission held a live Twitter chat to answer questions 
on antibiotic resistance. Dr. Marc Sprenger, Director of ECDC, and Dr. 
Tom Frieden joined forces to tweet messages to mark global action to 
slow the spread of antimicrobial resistance threats. This is the 5th year 
that ECDC has held an antibiotic awareness day. 
RDB’s Lauri Hicks is 
interviewed by Jeff Hullinger 
of Atlanta’s 11 Alive News 
during Get Smart About 
Antibiotics Week.
Cake promoting Get 
Smart Week at Children’s 
Hospital of Philadelphia.
Nearly Nine In 10 Believe Antibiotics Are 
Effective In Treating Bacterial Infections 
Very effective Somewhat effective Not too effective Not at all effective 
Bacterial infections 
such as strep throat 
or some sinus 
infections
Viral infections 
such as the flu or 
the common cold
Lauri Hicks and Arjun Srinivasan 
recording audio quotes for the Get 
Smart About Antibiotics Week digital 
press kit.
Teneva Hardy (right) acted as keyworker for the annual 
Combined Federal Campaign (CFC) at CDC. She has 
promoted campaign participation among staff in buildings 
23 and 24 for 2 years to support NCIRD’s efforts to raise 
funds for the world’s largest and most successful annual 
workplace charity campaign. Here, Teneva reviews contri-
bution options with DBD’s Tracey Pondo (left), who looks 
forward to supporting the campaign every year. The CFC 
allows federal employees and contractors to donate to a variety of organizations ranging from 
medical research to community improvement to youth development. NCIRD staff contributed 
$33, 604 to the campaign this year.
Stephen Hadler worked in the Polio Eradication Emergency Operations Center (EOC) much of 
the year as team lead for the Eastern Mediterranean Region, helping to guide CDC support for 
Pakistan and Afghanistan to implement emergency action plans to eradicate polio. Steve traveled 
to Afghanistan 3 times during the year to support this global health emergency. Other staff 
members from DBD involved in the polio eradication efforts include Sarah Meyer, who made two 





Helping to deliver a life-saving vaccine to 100 million 
DBD has a long history of involvement in Africa’s meningitis belt and 
under the guidance of MVPD branch chief Nancy Messonnier (pictured 
below 4th row, 2nd from left) activities continue to expand. Last spring, 
the Bill and Melinda Gates Foundation 
funded a meeting in Dakar, Senegal 
co-hosted by CDC and the London 
School of Tropical Hygiene and 
Medicine during which DBD subject 
matter experts helped to develop 
research priorities for meningococcal 
disease in Africa.  Current activities 
include working with ministries of health and global partners on post 
vaccine evaluations, lab training and other technical assistance. Staff 
are extremely proud to be a part of helping MenAfriVac® (the vaccine 
to protect against meningococcal A disease epidemics in sub Saharan 
Africa) to reach the 100 millionth person. The historic achievement came 
in early December during a seasonal immunization campaign in northern 
Nigeria—just two years after the vaccine was first launched in Burkina 
Faso. Since then, nine other countries have held vaccination campaigns 
to protect people from ages 1 to 29 against meningitis A. The vaccine 
can now be transported and stored for as long as four days without 
refrigeration or even an icepack—making  it the first vaccine intended 
for use in Africa approved for this type of use, potentially setting a 
regulatory path that other heat-stable vaccines can follow. With the 
vaccination campaigns planned in Nigeria, Cameroon and Chad,  by the 
end of this year, MenAfriVac®  will have reached more than 112 million 
people, providing widespread and long-awaited protection against 
meningococcal A disease epidemics. 
Marsha Houston represented the agency on the Global Coalition against 
Childhood Pneumonia, lending technical assistance to global activities 
for the 4th Annual World Pneumonia Day (http://worldpneumoniaday.
org/). DBD’s work on pneumonia was highlighted in a CDC Connects 
article on November 9. Alison Patti coordinated CDC Internet and social 
media exposure and the November issue of CDC’s Emerging Infectious 
Diseases Journal featured a commentary by Rana Hajjeh and Cynthia 
Whitney titled “Call to Action on World Pneumonia Day”, as well as 
articles on results of recent research on pneumonia.
Lauri Hicks presented “How to improve antibiotic prescribing practices” 




in pregnant women: a 
simulation approach” 
and Elizabeth Zell 
participated as a 
Governing Council 
representative for the 
statistics session at the 
140th American Public 
Health Association 
Annual Meeting and 
Exposition in San 
Francisco, CA.
Claressa Lucas presented “The CDC Legionella Lab: 35 years of 
surveillance” for a seminar series at Clemson University in Clemson, SC.
Lara Misegades was interviewed by JAMA about her DTaP vaccine 
effectiveness paper published in late November. The video story was 
distributed to US and Canada television. JAMA also recorded an author 
monologue video with Lara that was shared with JAMA subscribers.
Matt Moore presented “Pneumococcal vaccines across the lifespan” 
at the National Foundation for Infectious Diseases(NFID) Vaccinology 
Course in Miami, FL.
The 1st International Conference of the African Society for Laboratory 
Medicine (ASLM) was held December 1-7, 2012 in Cape Town, South 
Africa. Leonard Mayer (DBD/MVDPB) presented “The use of real-time 
PCR for laboratory diagnosis of bacterial meningitis.” Lesley McGee 




for enhancing laboratory 
diagnostic capacity for 
vaccine-preventable 
diseases” at an AFRO 
Regional Meeting on 
Immunization in Dar es 
Salaam, Tanzania.
Tami Skoff was a keynote speaker and presented “Coughing up the 
facts—pertussis epidemiology and emerging trends in the U.S.” at the 
Annual NY Emerging Infection Program Network 2-day roadshow in 
Buffalo, Rochester and Albany, NY.
During the Global Meeting on Immunization Monitoring and Surveillance 
in Washington, DC, Chris Van Beneden presented “Use of sentinel 
surveillance vs. population-based surveillance to accurately monitor the 
impact of pneumococcal conjugate vaccine” and “How best to present 
data from the IB VPD network? Common mistakes and suggestions for 
improvement.” For the Scientific Symposium on the Introduction of 
New Vaccines held in Haiti, Chris presented “Accelerating life-saving 
vaccine introduction—lessons from the Hib Initiative” and “Impact of 
pneumococcal conjugate vaccines in the U.S. following universal vaccine 
introduction.”
A new manual, Measuring impact of Streptococcus pneumoniae and 
Haemophilus influnzae type b conjugate vaccination (WHO/IVB/12.08), 
that describes approaches to measuring vaccine impact and a 
framework for determining the best methodology for use in different 
settings was posted on the WHO website (http://www.who.int/iris/
bitstream/10665/75835/1/WHO_IVB_12.08_eng.pdf). The manual was 
written by experts from the GAVI AVI-TAC Special Studies consortium 
and led by CDC/NCIRD scientists.
Rana Hajjeh (center) with CDC and hospital staff in Jeddah, 
Kingdom of Saudi Arabia (KSA), in October 2012. Rana 
led a team from CDC that included epidemiologists and 
microbiologists to assist KSA in investigating a case of a novel 
coronavirus diagnosed for the first time in the Kingdom. 
CDC worked with WHO and other international experts to 
determine the public health implications of this new virus. 
CDC assisted in building diagnostic capacity for this novel 
virus and provided technical guidance to health authorities, in preparation for the upcoming annual 
Muslim Hajj pilgrimage—the world’s largest annual religious gathering to the city of Mecca—that 
brings millions of people to KSA, to ensure early detection of additional cases and implementation 
of adequate prevention measures. No additional cases were reported during the Hajj season.
Tamara Pilishvili 





vaccine use for adults 
with high risk medical 
conditions.
Fabiana Pimenta, a microbiologist 
in DBD, conducts a training session 
on pneumococcal detection and 
serotyping with lab staff at the 
Universidad del Valle in Guatemala 
City.
Anne Schuchat, Acting Director 
of the Center for Global Health 
with Rana Hajjeh at the 5th 
GAVI Partners Forum at the 
Accelerated Vaccine Initiative-
Technical Assistance Consor-














Jonas Winchell and Stephanie Schrag presented at the ANISA 
(Aetiology of Neonatal Sepsis in Southeast Asia) Third Investigators’ 
Meeting in Phuket,Thailand. Jonas discussed further optimizations 
of the molecular testing procedures and TAC cards and Stephanie 
discussed progress on the Technical Advisory Group recommendations 
and presented on the project’s preliminary analysis of the multisite 
data. Cynthia Whitney and Lesley McGee also attended. ANISA is 
currently enrolling pregnant women and their newborns in Pakistan, 
Bangladesh, and India.
Elizabeth Zell and Tamara Pilishvili presented at the Vaccine 
Effectiveness (VE) Methods meeting in London, England. Rana 
Hajjeh, Jennifer Loo, Jennifer Verani, and Cindy Whitney 
attended sessions that discussed sources of bias in case control 
VE studies (Hib, pneumococcal, influenza and rotavirus vaccines), 
relevant studies, datasets and partners for future analytic work to 
understand biases, developing evaluation plans on important biases, 
and approaches to developing and disseminating recommendations. 
DBD was well represented during ID Week in San Diego, CA, 
this year:  Anna Acosta presented “Preventing pertussis in older 
adults: cost effectiveness analysis of a one-time tetanus toxoid-
reduced diphtheria toxoid-acellular pertussis (Tdap) dose in adults 
aged 65 years and older”; Kathleen Dooling presented the poster 
“Investigation of a prolonged group A streptococcal outbreak among 
residents of a skilled nursing facility, Georgia, 2009–2011”; Jennifer 
Liang presented “Rationale for changes to the Advisory Committee on 
Immunization Practices (ACIP) recommendations on the use of tetanus 
toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccines 
for pregnant women in the United States”; Matt Moore presented 
“Impact of 13-valent pneumococcal conjugate vaccine on invasive 
disease in the US”; Manisha Patel presented “Persistence of serogroup 
C antibody responses following quadrivalent meningococcal conjugate 
vaccination in US military personnel”; Jennifer Verani presented 
“Potential for further reduction of early-onset group B streptococcal 
disease in neonates”; and Jonathan Wortham presented “Burden of 
ambulatory visits and antibiotic prescribing for adults with community-
acquired pneumonia—United States, 1998–2009.”
Mark Your 2013 Calendar
 » Advisory Committee on Immunization Practices (ACIP) Meetings: February 20–21; June 19–20; October 23–24 at CDC in Atlanta, GA
 » National Foundation for Infectious Disease Clinical Vaccinology Course, March 8–10 in Chicago, IL
 » International Meeting on Emerging Diseases and Surveillance, (IMED) February 15–18 in Vienna, Austria: http://imed.isid.org/
 » Epidemic Intelligence Service (EIS) Conference, April 22–26 in Atlanta, GA
 » 16th Annual Conference on Vaccine Research, April 22–24 in Baltimore, MD
 » World Meningitis Day, April 24 
 » American Society for Microbiology (ASM) 113th General Meeting, May 18–21 in Denver, CO
 » 2013 APHL Annual Meeting & Seventh Government Environmental Laboratory Conference, June 2–5 in Raleigh, NC
 » National Immunization Conference, June 3–6 in Atlanta, GA
 » Group B Strep Awareness Month, July 2013
 » American Statistical Association Joint Statistical Meetings, August 3–8 in Montreal, Quebec
 » Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10–13 in Denver, CO
 » IDWeek 2013TM  Joint Meeting of IDSA, SHEA, HIVMA, and PIDS,  October 2–6 in San Francisco, CA
 » World Pneumonia Day, November 12
 » Get Smart About Antibiotics Week, November 18–24 
Reminders for 2013
 » Please help DBD maintain its history in photos...
 » Save posters presented at meetings and conferences to display during a DBD All-Hands Meeting.
 » Take photos of work activities here and in the field. Action shots are always great!
 » Submit articles accepted for publication to NCIRD’s Advance Media Report. Send to Alison Patti prior to online or print publication.
 » Make sure DBD OD knows about any awards you receive. Please forward these items to Alison Patti.
Rana Hajjeh, Vance Dietz (GID/
CGH), Peter Bloland (Director, 
CGH/DPHSWD) David Mekontso 
(Cameroun), Regis Mbarydaba 
(CAR) on a surveillance site visit 
to a district regional hospital in 
Cameroun in October.  
Leonard Mayer at the December African Society for 
Laboratory Medicine (ASLM) Conference in Cape Town, 
South Africa congratulates Dr. Rasmata  Ouedraogo 
Traore,  a professor of bacteriology-virology and close 
collaborator with DBD on its meningitis activities in  
Burkina Faso on receipt of an award.  DBD nominated 
Dr.  Rasmata for the ASLM Best Practice in laboratory 
Medicine in Africa Award for 2012.  Dr. Rasmata  says 
about the honor, “This recognition has been possible 
thanks to the CDC partners and commitment of 
Burkinabe particularly technical players in the labs.”   MVPDB has a long and on-going 
relationship with the Ministry of Health in Burkina Faso where CDC is conducting vaccine 
effectiveness studies following the introduction of MenAfriVac ® in 2010, and lending 
technical support and training for the country’s laboratories among other activities.
